Table 5.
Cardiac function variables
| Baseline | 60 minutes | 90 minutes | 120 minutes | 150 minutes | 180 minutes | 210 minutes | 240 minutes | 270 minutes | 300 minutes | |
|---|---|---|---|---|---|---|---|---|---|---|
| EEs slope (mmHg/ml) | ||||||||||
| Control | 1.01 (0.82 to 1.24) | 0.88 (0.71 to 1.08) | 0.69 (0.56 to 0.85) | 0.64 (0.52 to 0.79) | 0.73 (0.59 to 0.90) | 0.72 (0.58 to 0.88) | 0.81 (0.66 to 0.99) | 0.89 (0.72 to 1.09) | 0.94 (0.77 to 1.16) | 0.88 (0.71 to 1.08) |
| ALM | 0.86 (0.7 to 1.06) | 1.05 (0.82 to 1.34) | 0.79 (0.64 to 0.97) | 0.79 (0.65 to 0.98) | 0.81 (0.66 to 1.00) | 0.74 (0.60 to 0.91) | 0.78 (0.63 to 0.95) | 0.73 (0.60 to 0.90) | 0.82 (0.67 to 1.01) | 0.89 (0.72 to 1.10) |
| EEs V0 (ml) | ||||||||||
| Control | –38 (–56 to –20) | –40 (–58 to –22) | –64 (–82 to –45) | –63 (–81 to –45) | –51 (–69 to –32) | –47 (–65 to –28) | –25 (–43 to –7) | –10 (–28 to 9) | –5 (–23 to 13) | 0 (–18 to 18) |
| ALMa | –48 (–66 to –30) | –7 (–29 to 14) | –25 (–43 to –7) | –26 (–45 to –8) | –29 (–47 to –11) | –31 (–49 to –13) | –23 (–41 to –5) | –30 (–48 to –12) | –39 (–57 to –21) | –33b (–51 to –14) |
| PRSW slope (mmHg.ml/ml) | ||||||||||
| Control | 70 (58 to 84) | 50 (41 to 60) | 51 (42 to 61) | 42 (35 to 51) | 43 (36 to 52) | 38 (32 to 46) | 40 (33 to 48) | 33 (27 to 39) | 34 (28 to 41) | 36 (30 to 43) |
| ALMa | 70 (59 to 85) | 72 (59 to 88) | 64 (54 to 77) | 61 (51 to 74) | 57 (48 to 69) | 56 (46 to 67) | 48 (40 to 57) | 58 (48 to 70) | 66 (54 to 79) | 61b (51 to 74) |
| PRSW V0 (ml) | ||||||||||
| Control | 33 (22 to 44) | 24 (13 to 34) | 26 (15 to 37) | 10 (–1 to 21) | 23 (12 to 34) | 25 (14 to 35) | 45 (34 to 56) | 41 (30 to 52) | 51 (40 to 61) | 51 (40 to 61) |
| ALMa | 27 (16 to 38) | 43 (31 to 56) | 46 (35 to 57) | 43 (32 to 53) | 38 (27 to 48) | 41 (30 to 52) | 43 (32 to 54) | 52 (41 to 62) | 37c (26 to 48) | 45 (34 to 56) |
| Tau (milliseconds) | ||||||||||
| Control | 32 (29 to 35) | 30 (28 to 33) | 35 (32 to 38) | 35 (32 to 38) | 37 (34 to 40) | 38 (35 to 42) | 41 (38 to 45) | 44 (40 to 48) | 44 (41 to 48) | 44 (40 to 48) |
| ALMa | 31 (28 to 34) | 33 (30 to 36) | 31 (28 to 34) | 30 (28 to 33) | 32 (29 to 35) | 33 (30 to 36) | 35 (32 to 38) | 36 (33 to 39) | 37 (34 to 40) | 36b (33 to 39) |
| Aortic elastance (mmHg/ml) | ||||||||||
| Control | 1.3 (1.1 to 1.5) | 1.3 (1.1 to 1.5) | 1.2 (1.0 to 1.3) | 1.2 (1.1 to 1.4) | 1.5 (1.3 to 1.7) | 1.6 (1.4 to 1.9) | 1.9 (1.7 to 2.2) | 2.1 (1.8 to 2.4) | 2.2 (1.9 to 2.5) | 1.9 (1.7 to 2.2) |
| ALMa | 1.2 (1.1 to 1.4) | 0.9 (0.8 to 1.0) | 0.8 (0.7 to 1.0) | 0.9 (0.8 to 1.0) | 0.9 (0.8 to 1.0) | 0.9 (0.8 to 1.1) | 1.1 (0.9 to 1.2) | 1.1 (0.9 to 1.2) | 1.6c (1.4 to 1.9) | 1.5b (1.3 to 1.8) |
Data presented as median (95% confidence interval), except for Ees V0 and PRSW V0 which are presented as mean (95% confidence interval). ALM, adenosine, lidocaine and magnesium; Ees, end systolic elastance; PRSW, preload recruitable stroke work; V0, volume axis intercept. aSignificantly different change over time between groups. bSignificant difference at the end of the study. cSignificant difference before/after cessation ALM infusion.